Enrofloxacin is active against Gram-negative and Gram-positive bacteria.

**SIDE EFFECTS:**

A total of 845 calves with naturally-occurring BRD were treated with enrofloxacin in eight field trials located in five cattle-feeding states. Response to treatment was compared to non-treated controls. Single-dose and multiple-day therapy regimens were evaluated. BRD and mortality were significantly reduced in enrofloxacin-treated calves. No adverse reactions were reported in treated animals.

**EFFICACY:**

Enrofloxacin is active against Gram-negative and Gram-positive bacteria.

**ADVERSE REACTIONS:**

Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause dietary residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

**RESIDUE WARNINGS:**

Not for use in humans. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of contact with skin, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product.

**HUMAN WARNINGS:**

For 10 to 15 days. Clinical signs of toxicity were observed when a dose of 5 mg/kg was administered for 15 days. Clinical signs of depression, incoordination and muscle fasciculation were observed in calves when doses of 15 or 25 mg/kg were administered for 10 to 15 days. Clinical signs of toxicity or changes in clinical pathology parameters were observed when a dose of 50 mg/kg was administered for 3 days. No drug-related abnormalities in clinical pathology parameters were identified. No articular cartilage lesions were observed in the stiffe joints at any dose level at 2 days and 9 days following 15 days of drug administration. An injection site study conducted in feeder calves demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue and underlying muscle. No painful responses to administration were observed.

**STORAGE CONDITIONS:**

Protect from direct sunlight. Do not refrigerate or freeze. Store at 20-30°C (68-86°F), excursions permitted between 15°C (59°F) to 40°C (104°F). Precipitation may occur due to cold stress. Redissolve and then shake the vial.

**HOW SUPPLIED:**

Tenotryl™ (enrofloxacin) Injectable Solution: 100 mg/mL 100 mL Bottle 250 mL Bottle 500 mL Bottle

**REFERENCES:**


**ANIMAL SAFETY:**

Safely studies were conducted in feeder calves using single doses of 5, 15 and 25 mg/kg for 15 consecutive days and 50 mg/kg for 5 consecutive days. No clinical signs of toxicity were observed when a dose of 5 mg/kg was administered for 15 days. Clinical signs of depression, incoordination and muscle fasciculation were observed in calves when doses of 15 or 25 mg/kg were administered for 10 to 15 days. Clinical signs of toxicity or changes in clinical pathology parameters were observed when a dose of 50 mg/kg was administered for 3 days. No drug-related abnormalities in clinical pathology parameters were identified. No articular cartilage lesions were observed in the stiffe joints at any dose level at 2 days and 9 days following 15 days of drug administration. An injection site study conducted in feeder calves demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue and underlying muscle. No painful responses to administration were observed.

**STORAGE CONDITIONS:**

Protect from direct sunlight. Do not refrigerate or freeze. Store at 20-30°C (68-86°F), excursions permitted between 15°C (59°F) to 40°C (104°F). Precipitation may occur due to cold stress. Redissolve and then shake the vial.

**HOW SUPPLIED:**

Tenotryl™ (enrofloxacin) Injectable Solution: 100 mg/mL 100 mL Bottle 250 mL Bottle 500 mL Bottle

**REFERENCES:**


**ANIMAL SAFETY:**

Safely studies were conducted in feeder calves using single doses of 5, 15 and 25 mg/kg for 15 consecutive days and 50 mg/kg for 5 consecutive days. No clinical signs of toxicity were observed when a dose of 5 mg/kg was administered for 15 days. Clinical signs of depression, incoordination and muscle fasciculation were observed in calves when doses of 15 or 25 mg/kg were administered for 10 to 15 days. Clinical signs of toxicity or changes in clinical pathology parameters were observed when a dose of 50 mg/kg was administered for 3 days. No drug-related abnormalities in clinical pathology parameters were identified. No articular cartilage lesions were observed in the stiffe joints at any dose level at 2 days and 9 days following 15 days of drug administration. An injection site study conducted in feeder calves demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue and underlying muscle. No painful responses to administration were observed.

**STORAGE CONDITIONS:**

Protect from direct sunlight. Do not refrigerate or freeze. Store at 20-30°C (68-86°F), excursions permitted between 15°C (59°F) to 40°C (104°F). Precipitation may occur due to cold stress. Redissolve and then shake the vial.

**HOW SUPPLIED:**

Tenotryl™ (enrofloxacin) Injectable Solution: 100 mg/mL 100 mL Bottle 250 mL Bottle 500 mL Bottle

**REFERENCES:**


**ANIMAL SAFETY:**

Safely studies were conducted in feeder calves using single doses of 5, 15 and 25 mg/kg for 15 consecutive days and 50 mg/kg for 5 consecutive days. No clinical signs of toxicity were observed when a dose of 5 mg/kg was administered for 15 days. Clinical signs of depression, incoordination and muscle fasciculation were observed in calves when doses of 15 or 25 mg/kg were administered for 10 to 15 days. Clinical signs of toxicity or changes in clinical pathology parameters were observed when a dose of 50 mg/kg was administered for 3 days. No drug-related abnormalities in clinical pathology parameters were identified. No articular cartilage lesions were observed in the stiffe joints at any dose level at 2 days and 9 days following 15 days of drug administration. An injection site study conducted in feeder calves demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue and underlying muscle. No painful responses to administration were observed.